• CAS No.：
  474922-22-0
• Synonyms：
  DSPE-PEG-Maleimide
  
• Purity：
  ≥95%
• Recommended Storage Condition：
  Store at -5°C,keep in dry and avoid sunlight.
• Uses：
  Applicated in medical research, drug-release, nanotechnology and new materials research, cell culture. In the study of ligand, polypeptide synthesis support, a graft polymer compounds, new materials, and polyethylene glycol-modified functional coatings and other aspects of the active compound.

DSPE-PEG-Maleimide (DSPE-PEG-MAL) is one of phospholipid PEG derivatives that composed of DSPE (1,2-distearoyl-sn-glycero-3-phosphoethanolamine) and maleimide groups. DSPE-PEG-MAL is one of the most commonly used reactive phospholipids to conjugate antibodies, peptides or other ligands to the surface of liposome and other lipid PEG nanoparticles. Pegylated phospholipids have extended blood circulation time and higher stability for encapsulated drugs.

It is often used in targeted drug delivery with the lipid bilayer to improve drug solubility, the PEG to provide stealth property, extend circulation half-life and reduce non-specific protein binding or cell adhesion, and the reactive maleimide to bioconjugate targeting molecules including antibody, aptamer, protein, and peptide.

Biopharma PEG provides high purity DSPE-PEG-MAL with various molecular weights and excellent chemical reactivity. These lipid PEG conjugates demonstrate excellent amphilphilic properties and offer superior advantages for small and large molecule drug formulation and delivery. Email at sales@biochempeg.com for more information.

Cited Publications

This PEG derivative has been cited in peer-reviewed scientific publications. Browse the references below to learn more.

1. Lin TW, Chou PY, Shen YT, Sheu MT, Chuang KH, Lin SY, Chang CY. Tumor Antigen-Tethered Spiked Virus-Like- Poly(Lactic-Co-Glycolic Acid)-Nanoparticle Vaccine Enhances Antitumor, Ability Through Th9 Promotion in Mice. Int J Nanomedicine. 2024;19:10983-11002, https://doi.org/10.2147/IJN.S476715 
2. Young-Min Kim, Taeuk Guk, Mi-Kyeong Jang, Seong-Cheol Park, Jung Ro Lee,
   Targeted delivery of amphotericin B-loaded PLGA micelles displaying lipopeptides to drug-resistant Candida-infected skin, International Journal of Biological Macromolecules, Volume 279, Part 3, 2024, 135402, ISSN 0141-8130, https://doi.org/10.1016/j.ijbiomac.2024.135402. 
3. Lubitz, L.J.; Haffner, M.P.; Rieger, H.; Leneweit, G. Increased Cellular Uptake of ApoE3- or c(RGD)-Modified Liposomes for Glioblastoma Therapy Depending on the Target Cells. Pharmaceutics 2024, 16, 1112. https://doi.org/10.3390/pharmaceutics16091112 
4. Ben Mihoub, A.; Elkhoury, K.; Nel, J.; Acherar, S.; Velot, E.; Malaplate, C.; Linder, M.; Latifi, S.; Kahn, C.; Huguet, M.; et al. Neuroprotective Effect of Curcumin-Loaded RGD Peptide-PEGylated Nanoliposomes. Pharmaceutics 2023, 15, 2665. https://doi.org/10.3390/pharmaceutics15122665 
5. ​Mellinger A, Lubitz LJ, Gazaille C, et al. The use of liposomes functionalized with the NFL-TBS.40-63 peptide as a targeting agent to cross the in vitro blood-brain barrier and target glioblastoma cells. Int J Pharm. 2023;646:123421. doi:10.1016/j.ijpharm.2023.123421 
6. Kumar H, Gupta NV, Jain R, et al. F3 peptide functionalized liquid crystalline nanoparticles for delivering Salinomycin against breast cancer. Int J Pharm. 2023;643:123226. doi:10.1016/j.ijpharm.2023.123226 
7. Vári, B., Dókus, L., Borbély, A., Gaál, A., Vári-Mező, D., Ranđelović, I., … Tóvári, J. (2023). SREKA-targeted liposomes for highly metastatic breast cancer therapy. Drug Delivery, 30(1). https://doi.org/10.1080/10717544.2023.2174210 
8. Ashrafzadeh MS, Akbarzadeh A, Heydarinasab A, Ardjmand M. In vivo Glioblastoma Therapy Using Targeted Liposomal Cisplatin. Int J Nanomedicine. 2020;15:7035-7049
   https://doi.org/10.2147/IJN.S255902

View more publications citing Biopharma PEG products.